Takemasa Tsuji to Cancer Vaccines
This is a "connection" page, showing publications Takemasa Tsuji has written about Cancer Vaccines.
Connection Strength
1.095
-
Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res. 2013 Nov; 1(5):340-50.
Score: 0.420
-
Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination. J Immunol. 2009 Oct 01; 183(7):4800-8.
Score: 0.318
-
Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res. 2014 Jan; 2(1):37-49.
Score: 0.107
-
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 2012 Dec 01; 18(23):6497-508.
Score: 0.098
-
Inducing efficient cross-priming using antigen-coated yeast particles. J Immunother. 2008 Sep; 31(7):607-19.
Score: 0.074
-
Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes. Eur J Immunol. 2013 Apr; 43(4):989-1000.
Score: 0.025
-
Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity. Clin Cancer Res. 2012 Oct 01; 18(19):5449-59.
Score: 0.024
-
Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res. 2004 Dec 01; 64(23):8754-60.
Score: 0.014
-
The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. 2004 Sep; 95(9):697-703.
Score: 0.014